Anti-Pain Drugs Licensed To Lilly Boost Glenmark Earnings
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Glenmark Pharmaceuticals said it expects further earnings gains from a portfolio of anti-pain drugs licensed to Eli Lilly and from products in its pipeline as it reorganizes its business into specialty and generic units
You may also be interested in...
Glenmark’s Novel Molecule For Neuropathic Pain, Osteoarthritis To Enter Phase I Trials
MUMBAI - Indian drug maker Glenmark Pharmaceuticals' lead molecule for neuropathic pain, osteoarthritis and other inflammatory pain will enter Phase I trials shortly, the company announced, after filing for Phase I approval with European regulatory authorities
Glenmark’s Novel Molecule For Neuropathic Pain, Osteoarthritis To Enter Phase I Trials
MUMBAI - Indian drug maker Glenmark Pharmaceuticals' lead molecule for neuropathic pain, osteoarthritis and other inflammatory pain will enter Phase I trials shortly, the company announced, after filing for Phase I approval with European regulatory authorities
Ranbaxy Delays Spin Off Of R&D Unit Until Later This Year
NEW DELHI - Gurgaon, India-based Ranbaxy Laboratories has delayed plans to spin off its research unit until the second half of the year, but noted during a Jan. 17 press conference that it had settled a key lawsuit over Flomax (tamsulosin) and expanded a development deal with GlaxoSmithKline that will secure earnings momentum